“Bioglide” is a novel surface treatment for the silastic material used in fabrication of CSF shunts developed by Medtronic. The initial intention was to reduce infection risk, but early after its introduction there was hope that the surface treatment would reduce tissue adherence and proximal obstruction as well. These hypotheses have never been tested in a scientific fashion.
